Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.

Article Details

Citation

Copy to clipboard

Pollard JR

Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.

Curr Opin Investig Drugs. 2008 Jan;9(1):101-7.

PubMed ID

18183537 [ View in PubMed

]

Abstract

UCB SA was developing the high-affinity synaptic vesicle glycoprotein 2A ligand, seletracetam, an analog of levetiracetam, for the potential oral treatment of epilepsy. Phase II epilepsy trials were underway, but in July 2007, the company stated that development of seletracetam had been put on hold and it is unknown whether planned phase IIb/III trials will begin.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Seletracetam	Synaptic vesicle glycoprotein 2A	Protein	Humans	Yes	Modulator	Details